CA3249424A1 - Compounds targeting CXCR4, and their manufacturing and use processes - Google Patents

Compounds targeting CXCR4, and their manufacturing and use processes

Info

Publication number
CA3249424A1
CA3249424A1 CA3249424A CA3249424A CA3249424A1 CA 3249424 A1 CA3249424 A1 CA 3249424A1 CA 3249424 A CA3249424 A CA 3249424A CA 3249424 A CA3249424 A CA 3249424A CA 3249424 A1 CA3249424 A1 CA 3249424A1
Authority
CA
Canada
Prior art keywords
residue
compound
lys
independently
ipr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249424A
Other languages
English (en)
French (fr)
Inventor
François BÉNARD
Kuo-shyan Lin
Lee Lee LI
Zhengxing Zhang
Daniel KWON
David Perrin
Mihajlo Todorovic
Joseph Lau
Samson Lai
Hsiou-ting KUO
Original Assignee
Alpha 9 Oncology Inc
University of British Columbia
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 9 Oncology Inc, University of British Columbia, Provincial Health Services Authority filed Critical Alpha 9 Oncology Inc
Publication of CA3249424A1 publication Critical patent/CA3249424A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3249424A 2022-04-20 2023-04-20 Compounds targeting CXCR4, and their manufacturing and use processes Pending CA3249424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332885P 2022-04-20 2022-04-20
US63/332,885 2022-04-20
PCT/CA2023/050538 WO2023201435A1 (en) 2022-04-20 2023-04-20 Cxcr4-targeting compounds, and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA3249424A1 true CA3249424A1 (en) 2023-10-26

Family

ID=88418769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249424A Pending CA3249424A1 (en) 2022-04-20 2023-04-20 Compounds targeting CXCR4, and their manufacturing and use processes

Country Status (7)

Country Link
US (1) US20250242064A1 (https=)
EP (1) EP4511384A1 (https=)
JP (1) JP2025513489A (https=)
CN (1) CN119325480A (https=)
AU (1) AU2023257191A1 (https=)
CA (1) CA3249424A1 (https=)
WO (1) WO2023201435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用
CN120137854B (zh) * 2025-05-13 2025-09-23 中国农业大学 一种具有广泛pH适应性的有机磷矿化复合菌群及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377579A1 (en) * 2007-05-30 2011-10-19 Eli Lilly and Company Cyclic peptide CXCR4 antagonists
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
JP2023549469A (ja) * 2020-10-21 2023-11-27 プロビンシャル・ヘルス・サービシーズ・オーソリティ 新規ｃｘｃｒ４標的化合物

Also Published As

Publication number Publication date
CN119325480A (zh) 2025-01-17
JP2025513489A (ja) 2025-04-24
EP4511384A1 (en) 2025-02-26
WO2023201435A1 (en) 2023-10-26
WO2023201435A8 (en) 2023-12-28
US20250242064A1 (en) 2025-07-31
AU2023257191A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7659268B2 (ja) デュアルモード１８ｆ標識セラノスティック化合物及びその使用
US11395857B2 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
IL301342A (en) Novel cxcr4-targeting compounds
US20210402016A1 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
US20250161501A1 (en) Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders
CA3244865A1 (en) RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CA3249424A1 (en) Compounds targeting CXCR4, and their manufacturing and use processes
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
US12616761B2 (en) CXCR4-targeting compounds
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241017

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241113

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241113

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260407